N/A N=58 Nano-Pulse Stimulation (NPS) in Seborrheic Keratosis Study
Lesion Skin · Seborrheic Keratosis
Primary: Clearance of SK Lesions — 82 percentage of SK lesion clearance
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=35 Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis
Seborrheic Keratosis (SK)
Primary: Mean Change in Physician Lesion Assessment Scale — -0.47; -0.88; -1.12; -0.15 Change in Score on a scale
Phase 2 N=253 A Randomized, Vehicle-Controlled Study of 2 Concentrations of A-101 for the Treatment of Seborrheic Keratosis
Seborrheic Keratosis
Primary: Mean of Per Subject Percentages of Target Lesions Judged to be Clear (PWA=0) at Visit 8 — 3.72; 49.5; 57.88 Per-Subject Percent of Lesions Clear
Phase 3 N=450 A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis.
Seborrheic Keratosis
Primary: Proportion of Subjects With Target Lesion Clearance as Assessed by the Physician Lesion Assessment — 9; 0 Participants
Phase 4 N=41 An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses
Seborrheic Keratosis
Primary: Subject Satisfaction — 21; 14; 4; 0 Participants
Phase 2 N=172 Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis
Seborrheic Keratosis
Primary: Mean Per Subject Percentage Target Lesions Judged Clear by the Physician's Lesion Assessment (PLA) — 4.82; 26.79; 45.09 percentage of lesions cleared — p=0.0003
Phase 2 N=119 Study of A-101 for the Treatment of Seborrheic Keratosis
Seborrheic Keratosis
Primary: Percentage of PLA Responders With Target Lesion Clear (PLA = 0) in Each Arm at Visit 8. — 22; 18; 1 Participants — p=<0.0001
Phase 3 N=487 A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis
Seborrheic Keratosis
Primary: Proportion of Subjects With All Target Lesions Cleared According to Physician Lesion Assessment Scale — 19; 0 Participants
N/A N=10 Dermatosis Papulosa Nigra
Facial Dermatoses · Seborrheic Keratoses
Primary: Percent Clearance of All Lesions — 88; 96; 92.5; 0 percentage of lesion clearance
Phase 4 N=551 Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis
Keratosis
Primary: Number of Participants Who Experienced an Adverse Event — 472 participants
Phase 2 N=168 Activity & Safety Study of KX2-391 Ointment in Participants With Actinic Keratosis on the Face or Scalp
Actinic Keratosis
Primary: Percentage of Participants With Complete Response of Actinic Keratosis — 43; 32 percentage of participants
Phase 3 N=490 Safety and Effectiveness Study of Imiquimod Creams for the Treatment of Actinic Keratoses (AKs)
Actinic Keratosis
Primary: Number of Participants With Complete Clearance of AK Lesions — 55; 41; 9 participants
N/A N=20 Efficacy and Safety of Tixel Treatment on Facial and/or Scalp Actinic Keratoses.
Actinic Keratoses
Primary: Efficacy of Tixel for Treatment of Actinic Keratosis — -90.4 percentage change
Phase 3 N=479 Safety and Effectiveness Study of Imiquimod Creams for Treatment of Actinic Keratoses (AKs)
Actinic Keratoses
Primary: Number of Participants With Complete Clearance of AK Lesions — 57; 49; 10 participants
Phase 3 N=351 A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on Actinic Keratosis on Face or Scalp (AK004)
Actinic Keratosis
Primary: Percentage of Participants With Complete (100%) Clearance of Actinic Keratosis (AK) Lesions — 13; 54 percentage of participants — p=<0.0001
Phase 2 N=189 Safety of LEO 43204 for Actinic Keratosis Applied on Face/Chest, Scalp and Trunk/Extremities, Respectively
Actinic Keratosis
Primary: Number of Participants Experiencing DLTs (Dose Limiting Toxicities) Based on LSRs (Local Skin Reactions) — 9; 0; 11 Participants
Phase 3 N=351 A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp
Actinic Keratoses
Primary: Percentage of Participants With Complete (100%) Clearance of Actinic Keratosis (AK) Lesions — 5; 44 percentage of participants — p=<0.0001
Phase 2 N=12 Preventing Squamous Cell Skin Cancer
Squamous Cell Carcinoma of the Skin
Primary: Mean Number of Squamous Cell Carcinomas — 0.75; 1.00 # of squamous cell carcinomas — p=0.750
N/A N=72 Nano-Pulse Stimulation (NPS) in Sebaceous Hyperplasia
Skin Lesion · Skin Abnormalities · Sebaceous Hyperplasia
Primary: Total Number of Cleared SH Lesions — 99.5 Percentage of cleared SH Lesions
Phase 3 N=450 Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp
Actinic Keratosis
Primary: Number of Participants With Complete Clearance of AKs 8 Weeks After Randomisation — 43; 9; 25; 5 participants — p=0.001
N/A N=776 A Retrospective Evaluation of Superficial Radiation Therapy (SRT) and Non-Melanoma Skin Cancer (NMSC)
Non-melanoma Skin Cancer
Primary: Cure Rate — 751 lesions
Phase 2 N=165 The Efficacy and Tolerability of Oleogel-S-10 in Patients With Actinic Keratoses
Actinic Keratoses
Primary: Objective Response of the Marker Actinic Keratosis, Defined as Histologically Complete or Partial Clearance. — 22; 17; 19; 25 participants — p=0.60
Phase 2 N=33 Study of SOR007 Ointment for Actinic Keratosis
Actinic Keratosis
Primary: Number of Participants With Treatment Emergent Adverse Events — 2; 1; 3; 1 Participants
Phase 2 N=21 Genomic Markers Before and After Treatment of Actinic Keratosis With Imiquimod 3.75% Cream
Actinic Keratosis
Primary: Number of Responders — 19 Participants
Phase 3 N=147 An Open-Label Safety Study of A-101 Solution
Seborrheic Keratosis
Primary: Proportion of Subjects With Lesion Clearance — 16 Participants
Phase 4 N=77 Clinical Trial of Ingenol Mebutate Gel 0.015% & 0.05% in Actinic Keratosis
Actinic Keratosis
Primary: CC Rate of AK Lesions in the Selected Treatment Area — 49; 8; 15; 1 Participants
Phase 3 N=26 Actinic Keratoses Treatment With Metvix® in Combination With Light
Actinic Keratoses
Primary: Mean Change From Baseline in Total Number of Treated Mild Lesions Per Side at Week 12 — 19.6; 20.0 number of lesions — p=0.8460
Phase 2 N=69 Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis
Actinic Keratosis
Primary: Part 1: Participants Experiencing Dose Limiting Toxicity (DLT) Based on Local Skin Responses (LSRs) — 0; 0; 2; 1 Participants
Phase 3 N=729 Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Chest
Actinic Keratosis
Primary: Percentage of Participants With Complete Resolution of Actinic Keratosis (AK) — 21.4; 3.4 percentage of participants — p=<0.001
Phase 2 N=83 Study to Evaluate the Efficacy, Safety, and Tolerability of Topical VDA-1102 Ointment in Subjects With Actinic Keratosis
Actinic Keratosis
Primary: Complete Clearance Rate — 7; 9 Participants